Media ReleasesImugene Limited

View All Imugene Limited News

Imugene Announces New Data on Lead PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines Presented at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia, 2 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The highlight and key finding of the KEY-Vaxx presentation demonstrated that KEY-Vaxx when combined with B-Vaxx is more effective in reducing tumor growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone, or more importantly the positive control gold standard anti-mouse PD-1 monoclonal antibody. The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity. Imugene is working to evaluate KEY-Vaxx and its potential efficacy in a range of cancers.

For further information please download PDF attached:
Download this document